ImmunityBio (IBRX) Equity Income (2020 - 2021)
ImmunityBio's (IBRX) quarterly Equity Income came in at -$442000.0 in Q2 2021, down 163.87% year-on-year from $692000.0 in Q2 2020, and down 163.87% on a QoQ basis from $692000.0 in Q2 2020.
ImmunityBio (IBRX) Equity Income (2020 - 2021) Analysis & Trends
ImmunityBio (IBRX) has 2 years of Equity Income data on file, last reported at -$442000.0 in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | ImmunityBio | 7.35 Bn | 6.97 Bn | 43.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | -442,000.00 |
| Jun 30, 2020 | 692,000.00 |